Latest news with #RIGL
Yahoo
10-07-2025
- Business
- Yahoo
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 3, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) and set a price target of $57.00. The optimistic rating was based on the company's prospects, including promising results from the ARROW trial for GAVRETO. A researcher in a lab coat monitoring a biotechnological experiment. The trial demonstrated safety and strong efficacy for the treatment of RET fusion-positive NSCLC and other solid tumors. It also exhibited a significant median duration of response and a high overall response rate, pointing towards the drug's meaningful and durable outcomes. The analyst further reasoned that the trial data shows GAVRETO's optimistic anti-tumor activity across a number of RET fusion-positive solid tumors, which shows its market potential and paints an optimistic picture for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a clinical-stage biotechnology company that discovers and develops targeted, novel drugs in oncology, immunology, and immune oncology. Its product portfolio includes Tavalisse, Fostamatinib, and R835. While we acknowledge the potential of RIGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
28-03-2025
- Automotive
- Yahoo
How do I register my golf cart?
− Robert F. A: This is from our website ( regarding LSV and golf carts. It can be found in the 'Registration, Plates & Titles' tab and in the 'Registration' tab. Read more: Where can I have my golf cart inspected? | Ask the RI DMV Effective July 1, 2024, in accordance with RIGL § 31-19.6 -1, Low-speed Vehicles as defined in RIGL § 31-1-3 (l), may be registered for use on public roads with posted speed limits up to 35 mph. These vehicles are to be registered, insured and inspected in accordance with the Rhode Island laws and regulations established for motor vehicles. A municipality may, by ordinance, prohibit the operation of low-speed vehicles on a laned roadway or local highway or a portion of a highway within its jurisdiction and under its control. It is highly recommended that you check with your local city or town BEFORE purchasing a low-speed vehicle. Municipalities without their own low-speed vehicle laws will operate under state law. Municipalities may choose to adopt local LSV ordinances at any time. The following municipalities have provided the RI DMV with LSV information specific to their city or town, as of September 2024: Providence, Westerly, Portsmouth and West Warwick (links to their information is on our website.) What qualifies as a low-speed vehicle (LSV): A "low-speed vehicle" (LSV) is any four-wheeled motor vehicle that: Is exclusively electric powered; and Has been issued a certificate of origin; and Has a gross vehicle weight rating (GVWR) of less than 3,000 pounds; and Has a top speed greater than 20 mph but not greater than 25 mph; and Is National Highway Traffic Safety Administration (NHTSA)-certified to the standards established in 49 C.F.R. § 571.500, as a "low-speed vehicle,' demonstrated by: The certificate of origin, title, or out-of-state registration listing the body style or body type as "LSV" or "low-speed vehicle "; and/or: The manufacturer's certification label posted on the vehicle containing the VIN and indicating the type of vehicle as a "low-speed vehicle." IMPORTANT NOTE: Golf carts are not manufactured to low-speed vehicle standards and therefore may NOT be registered as low-speed vehicles. How to register a low-speed vehicle (LSV): An application for registration and title certificate (TR-1) must be completed and signed by the owner(s). The completed application must be accompanied by one of the following documents: A manufacturer's' certificate of origin (new vehicles only), or The previous owner's certificate of title listing the body style or body type as "LSV" or " low-speed vehicle," or The previous registration and bill of sale (for vehicles that are from states where the vehicle was exempt from titling requirements) Effective Jan. 1, 2024 ALL VEHICLES registered or titled in another state, regardless of model year, require a VIN Check from a local municipal police department prior to registration in Rhode Island. Only new vehicles NEVER titled or registered in another state are exempt from this requirement. Low-speed vehicles must be insured with a policy meeting the minimum Rhode Island liability insurance requirements for on-road vehicles. Off-road vehicle insurance policies are not acceptable and may result in the registration being revoked and a reinstatement fee. Bring the completed TR-1 application form, as well as all other required documents (as listed on the Registration Document Checklist), along with the required DMV fees to the DMV at the time of your reservation for a new title and registration transaction. Reservations can be made at This area can be found on the front page of the DMV's website. Only low-speed vehicle plates will be available and be issued to LSVs. Low-speed vehicles, bearing low-speed vehicle plates, may bear lettering and be used for commercial purposes. Low-speed vehicle (LSV) Operator Licensing requirements: A valid driver's license is required to operate a low-speed vehicle. Operating a low-speed vehicle (LSV): To be on a public way, LSVs must be registered, titled, insured and inspected. Low-speed vehicles may be operated on any state highway, through highway, limited access highway or public highway or roadway with a posted speed limit of thirty-five miles per hour (35 m.p.h.) or less. No low-speed vehicle shall operate on any state highway, through highway, limited access highway or public highway or roadway with a speed limit greater than thirty-five miles per hour (35 m.p.h.). As mentioned above, local cities and towns may have their own ordinances regarding low-speed vehicles. It is highly recommended that you check with your local city or town BEFORE purchasing a low-speed vehicle. Low-speed vehicle (LSV) Inspection requirements: Low-speed vehicles shall be inspected in accordance with the law and shall display a valid unexpired RI certificate of inspection (inspection sticker) or shall be required to pass such an inspection within five business days from the date of registration. New low-speed vehicles are exempt from inspection for two years or 24,000 miles from the date of purchase, whichever occurs first. I hope this information helps you. If you have further questions, you can reach out to the DMV's Safety & Emissions Office. Chuck Hollis is assistant administrator of the Rhode Island Division of Motor Vehicles. Please email your questions to cars@ with 'Ask the DMV' in the subject field. This article originally appeared on The Providence Journal: How do I register my golf cart? | Ask the RI DMV
Yahoo
04-03-2025
- Business
- Yahoo
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
Rigel Pharmaceuticals, Inc. RIGL is set to report its fourth-quarter and full-year 2024 earnings on March 4. The Zacks Consensus Estimate for sales and earnings is pegged at $57.57 million and 42 cents per share, respectively. The Zacks Consensus Estimate for 2024 earnings per share (EPS) has increased to 22 cents from 17 cents over the past 60 days. The EPS estimate for 2025 has also jumped 13 cents to $1.05. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. Image Source: Zacks Investment Research RIGL beat on earnings in three of the trailing four quarters and missed in the other, delivering an average surprise of 1,754.3%. In the last reported quarter, the company delivered an earnings surprise of 6,900%, as seen in the chart below. Image Source: Zacks Investment Research RIGL has an Earnings ESP of 0.0% and a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Rigel's first approved product Tavalisse (fostamatinib disodium hexahydrate) showed encouraging uptake in 2024. The drug is the only approved oral SYK inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The drug is also approved in the EU, UK and Japan. Last month, Rigel provided preliminary results for the fourth quarter and full year of 2024, along with its outlook for 2025. RIGL expects total revenues of $57.6 million in the fourth quarter, up from $35.8 million in the year-ago period. Rigel expects quarterly net product sales of $46.5 million and sales of $31.0 million for Tavalisse. The company is also making good progress with its second FDA-approved product, Rezlidhia (olutasidenib). The drug is indicated for the treatment of adult patients with relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AM R/R AML with a susceptible IDH1 mutation as detected by an FDA-approved test. Rigel in-licensed the drug from Forma with exclusive, worldwide rights for its development, manufacturing and commercialization. Rigel expects to report Rezlidhia net product sales of $7.4 million. It entered into an exclusive license agreement with Dr. Reddy's RDY in November to develop and commercialize Rezlidhia in all potential indications throughout Dr. Reddy's territory, which includes Latin America, South Africa, certain countries in the Commonwealth of Independent States (CIS), India, certain countries in Southeast Asia and North Africa, Australia and New Zealand. The company added a third product, Gavreto, to its commercial portfolio in 2024. The drug was added to RIGL's portfolio after the company acquired commercial rights of the drug from Blueprint Medicines Corporation BPMC. Gavreto became commercially available from Rigel in June 2024. RIGL expects to report Gavreto net product sales of $8.1 million. Contract revenues from collaborations during the fourth quarter are expected to be approximately $11.1 million. This includes a $4.0 million upfront cash payment from RDY; $3.6 million of revenues from Grifols S.A. related to the delivery of drug supplies and earned royalties; $2.9 million of revenues from Kissei Pharmaceutical related to the delivery of drug supplies; and $0.3 million of revenues from Medison Pharma Trading AG pertaining to delivery of drug supplies and earned royalties. For 2024, Rigel expects to report total revenues of $179.3 million, including net product sales of $144.9 million and contract revenues from collaborations of $34.4 million. It expects to report cash, cash equivalents, and short-term investments of approximately $77.3 million for the quarter. Rigel's shares have surged 50.6% in the past year against the industry's decline of 13.4%. Image Source: Zacks Investment Research Going by the price/sales ratio, RIGL's shares currently trade at 1.86x forward sales, lower than its mean of 2.37x but higher than 1.64x for the drug industry. Image Source: Zacks Investment Research Rigel's lead drug Tavalisse showed encouraging uptake in 2024. Tavalisse has likely generated $104.8 million in net product sales in 2024. Sales in 2025 should increase further. Rezlidhia is also showing good traction. Incremental contribution from Gavreto boosted the company's top line in 2024. These three drugs should help maintain momentum for the company. Rigel anticipates total revenues of approximately $200-$210 million in 2025, including product sales of approximately $185-$192 million. The company also expects to report positive net income in 2025 while funding existing and new clinical development programs. Apart from these approved drugs, RIGL is developing other drugs, and the pipeline progress has been encouraging. Last month, the FDA granted Orphan Drug designation to R289, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, for the treatment of myelodysplastic syndromes (MDS). RIGL is evaluating the candidate in an ongoing phase Ib study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with lower-risk myelodysplastic syndromes (LR-MDS) who are relapsed or refractory to prior therapies. The candidate was also granted Fast Track designation by the regulatory body for this indication. We are optimistic about RIGL, buoyed by its strong performance in 2024 and upbeat guidance for 2025. Growth in Tavalisse sales should fuel top line. Contributions from its other drugs should also boost sales. A single quarter's results are not important for long-term investors. Given RIGL's current valuation, we believe there is more room for growth and recommend prospective investors to add the stock to their portfolio. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dr. Reddy's Laboratories Ltd (RDY) : Free Stock Analysis Report Rigel Pharmaceuticals, Inc. (RIGL) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
